AOD-14 vs GHR Peptide-6
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, AOD-14 or GHR Peptide-6?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between AOD-14 and GHR Peptide-6?
GHR-peptide-6 is a growth hormone releasing peptide acting on ghrelin receptors with characterized GH secretagogue and cytoprotective effects; AOD-14 lacks any published mechanistic characterization.
Evidence Comparison
GHR-peptide-6 (GHRP-6): publications primarily from a single Cuban research group (Berlanga-Acosta et al.) studying wound healing, cytoprotection, and GH secretion. AOD-14: no identifiable peer-reviewed publications. GHR-peptide-6 has some published data; AOD-14 has none.
Evidence Context Favoring AOD-14
There is no evidence-based scenario supporting AOD-14 given the absence of peer-reviewed literature.
Evidence Context Favoring GHR Peptide-6
GH secretagogue or cytoprotection research, accepting that the evidence base is narrow and comes primarily from one research group. Note: GHRP-6 is WADA prohibited.
Side-by-Side Snapshot
| Evidence grade | AOD-14: Level D GHR Peptide-6: Level D |
|---|---|
| Research status | AOD-14: Early Research GHR Peptide-6: Preclinical |
| Primary category | AOD-14: Healing & Recovery GHR Peptide-6: Healing & Recovery |
| Cited studies | AOD-14: 2 GHR Peptide-6: 2 |